SUPPORTING INFORMATION

Structure-activity relationship studies of the aromatic positions in cyclopentapeptide CXCR4 antagonists

Jignesh Mungalpara, \ddagger^a Zack G. Zachariassen, \ddagger^a Stefanie Thiele,^b Mette M. Rosenkilde,^b and Jon Våbenø^{*a}

^a Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Breivika, NO-9037 Tromsø, Norway. Fax: +47 77 64 61 51; Tel: +47 77 62 09 09; E-mail: <u>jon.vabeno@uit.no</u>.

^b Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.

‡ These authors contributed equally to this work.

Table of contents

Antagonistic potency of 2 and the analogues 4–22 on human CXCR4 (Table S1)	S2
Yields and HRMS data for compounds 4-22 (Table S2)	S3
¹ H and ¹³ C NMR data	S4-S8
¹ H and ¹³ C NMR spectra	S9-S25
HPLC chromatograms	S26-S28

No.	Compound ^a	$\log EC_{50} \pm SEM^b$	EC ₅₀ (µM)
2 ^{<i>c</i>}	FC131	-6.40 ± 0.04	0.40
4	[Phg ³]FC131	>-4	>100
5	[Phe ³]FC131	>-4	>100
6	[Cha ³]FC131	>-4	>100
7	[Hph ³]FC131	-4.51 ± 0.30	31
8	[Hch ³]FC131	-4.54 ± 0.14	29
9	[Bsa ³]FC131	-4.71 ± 0.07	19
10	[1-Nal ³]FC131	-5.25 ± 0.08	5.6
11	[Pph ³]FC131	>-4	>100
12	[Bph ³]FC131	>-4	>100
13 ^c	[Ala ³]FC131	>_4	>100
14 ^c	[D-Phe ⁵]FC131	-6.07 ± 0.05	0.85
15	[Aic ⁵]FC131	-4.13 ± 0.19	74
16	[D-Tic ⁵]FC131	-4.60 ± 0.02	25
17^{d}	[<i>trans</i> -Ppr ⁵]FC131	-4.46 ± 0.14	35
18 ^e	[<i>cis</i> -Ppr ⁵]FC131	-4.43 ± 0.18	37
19	[D-Pic ⁵]FC131	>-4	>100
20	[D-Pro ⁵]FC131	>-4	>100
21 ^c	[D-Ala ⁵]FC131	-4.29 ± 0.08	51
22	[Gly ⁵]FC131	-5.29 ± 0.16	5.1

Table S1. Antagonistic potency of 2 and the analogues 4–22 on human CXCR4.

^{*a*} 1-Nal = 3-(1-naphthyl)alanine; Aic = 2-aminoindan-2-carboxylic acid; Bph = 4benzoylphenylalanine; Bsa = β -styrylalanine; Cha = 3-cyclohexylalanine; Hch = 2-amino-4cyclohexylbutanoic acid; Hph = 2-amino-4-phenylbutanoic acid; Phg = phenylglycine; Pic = pipecolic acid; Pph = 4-phenylphenylalanine; Ppr = 3-phenyl-Pro; Tic = tetrahydroisoquinoline-3carboxylic acid. ^{*b*} Inhibition of C-X-C chemokine ligand 12 (CXCL12) induced activation of human CXCR4. Values represent the mean of at least three independent experiments performed in duplicate. ^{*c*} Known compounds; see main text. ^{*d*} Tested as a 47:53 mixture of the two diastereomers. ^{*e*} Tested as a 68:32 mixture of the two diastereomers.

mpounds 4-22.
for co
data 1
HRMS
and l
Yields
Table S2.

		* 7 • 1 1 8			+
Compd	Sequence	Y 1eld (%)	Mol Formula	[M+H] calcd	obsd ^b
4	cyclo(-Arg ¹ -Arg ² -Phg ³ -Gly ⁴ -D-Tyr ⁵ -) \times 2 TFA	8.5	$C_{31}H_{43}N_{11}O_6$	666.3471	666.3469
S	$cyclo(-Arg^{1}-Arg^{2}-Phe^{3}-Gly^{4}-D-Tyr^{5}-)\times 2\ TFA$	24	$C_{32}H_{45}N_{11}O_6$	680.3627	680.3627
9	$cyclo(-Arg^{1}-Arg^{2}-Cha^{3}-Gly^{4}-D-Tyr^{5}-)\times 2\ TFA$	28	$C_{32}H_{51}N_{11}O_6$	686.4097	686.4096
٢	$cyclo(-Arg^{1}-Arg^{2}-Hph^{3}-Gly^{4}-D-Tyr^{5}-) \times 2 TFA$	6.5	$C_{33}H_{47}N_{11}O_6$	694.3784	694.3786
œ	$cyclo(-Arg^{1}-Arg^{2}-Hch^{3}-Gly^{4}-D-Tyr^{5}-) \times 2 TFA$	29	$C_{33}H_{53}N_{11}O_6$	700.4253	700.4253
6	$cyclo(-Arg^{1}-Arg^{2}-Bsa^{3}-Gly^{4}-D-Tyr^{5}-)\times 2\ TFA$	5.7	$C_{34}H_{47}N_{11}O_6$	706.3784	706.3784
10	$cyclo(-Arg^{1}-Arg^{2}-1-Nal^{3}-Gly^{4}-D-Tyr^{5}-)\times 2\ TFA$	29	$C_{36}H_{47}N_{11}O_6$	730.3784	730.3786
11	$cyclo(-Arg^{1}-Arg^{2}-Pph^{3}-Gly^{4}-D-Tyr^{5}-) \times 2 TFA$	28	$C_{38}H_{49}N_{11}O_6$	756.3940	756.3944
12	$cyclo(-Arg^{1}-Arg^{2}-Bph^{3}-Gly^{4}-D-Tyr^{5}-) \times 2 TFA$	18	$C_{39}H_{49}N_{11}O_7$	784.3889	784.3891
13	$cyclo(-Arg^{1}-Arg^{2}-Ala^{3}-Gly^{4}-D-Tyr^{5}-)\times 2\ TFA$	34	$C_{26}H_{41}N_{11}O_6$	604.3314	604.3314
14	$cyclo(-Arg^{1}-Arg^{2}-2-Nal^{3}-Gly^{4}-D-Phe^{5}-) \times 2 TFA$	19	$C_{36}H_{47}N_{11}O_5$	714.3834	714.3840
15	$cyclo(-Arg^{1}-Arg^{2}-2-Nal^{3}-Gly^{4}-Aic^{5}-) \times 2 TFA$	26	$C_{37}H_{47}N_{11}O_5$	726.3834	726.3834
16	$cyclo(-Arg^{1}-Arg^{2}-2-Nal^{3}-Gly^{4}-D-Tic^{5}-) \times 2 TFA$	28	$C_{37}H_{47}N_{11}O_5$	726.3834	726.3831
17	$cyclo(-Arg^{1}-Arg^{2}-2-Nal^{3}-Gly^{4}$ - <i>trans</i> -Ppr ⁵ -) × 2 TFA	34	$C_{38}H_{49}N_{11}O_5$	740.3991	740.3987
18	$cyclo(-Arg^{1}-Arg^{2}-2-Nal^{3}-Gly^{4}-cis-Ppr^{5}-) \times 2 TFA$	9.8	$C_{38}H_{49}N_{11}O_5$	740.3991	740.3985
19	$cyclo(-Arg^{1}-Arg^{2}-2-Nal^{3}-Gly^{4}-D-Pic^{5}-) \times 2 TFA$	17	$C_{33}H_{47}N_{11}O_5$	678.3834	678.3841
20	$cyclo(-Arg^{1}-Arg^{2}-2-Nal^{3}-Gly^{4}-D-Pro^{5}-)\times 2~TFA$	28	$C_{32}H_{45}N_{11}O_5$	664.3678	664.3674
21	$cyclo(-Arg^{1}-Arg^{2}-2-Nal^{3}-Gly^{4}-D-Ala^{5}-)\times 2~TFA$	18	$C_{30}H_{43}N_{11}O_5$	638.3521	638.3529
22	$cyclo(-Arg^{1}-Arg^{2}-2-Nal^{3}-Gly^{4}-Gly^{5}-) \times 2 TFA$	28	$C_{29}H_{41}N_{11}O_5$	624.3365	624.3374
^a Calculate	ed from resin. ^b HRMS ESI+.				

¹H and ¹³C NMR data

cyclo(-Arg¹-Arg²-Phg³-Gly⁴-D-Tyr⁵-) × 2 TFA (4). ¹H NMR (400 MHz, CD₃OD): δ 7.48 – 7.30 (m, 5H), 7.05 (d, *J* = 8.4 Hz, 2H), 6.72 (d, *J* = 8.4 Hz, 2H), 5.56 (s, 1H), 4.40 – 4.31 (m, 2H), 4.08 (d, *J* = 15.1 Hz, 1H), 4.00 (dd, *J* = 11.2, 3.8 Hz, 1H), 3.60 (d, *J* = 15.1 Hz, 1H), 3.23 – 3.09 (m, 2H), 3.08 – 2.77 (m, 4H), 2.03 – 1.77 (m, 2H), 1.62 – 1.34 (m, 4H), 1.34 – 1.06 (m, 2H). ¹³C NMR (100 MHz, CD₃OD): δ 172.6, 172.4, 172.2, 171.0, 170.6, 157.2, 157.2, 155.9, 135.0, 130.1, 128.2, 128.0, 127.2, 127.1, 115.0, 57.7, 56.6, 53.9, 53.1, 44.5, 42.7, 40.6, 40.1, 35.9, 28.3, 27.8, 24.8. cyclo(-Arg¹-Arg²-Phe³-Gly⁴-D-Tyr⁵-) × 2 TFA (5). ¹H NMR (400 MHz, CD₃OD): δ 7.29 – 7.16

(m, 5H), 7.02 (d, J = 6.5 Hz, 2H), 6.71 (d, J = 6.5 Hz, 2H), 4.50 – 4.41 (m, 1H), 4.34 – 4.28 (m, 1H), 4.23 – 4.16 (m, 1H), 4.07 – 4.04 (m, 1H), 4.01 (d, J = 15.7 Hz, 1H), 3.68 (d, J = 15.7 Hz, 1H), 3.21 – 3.06 (m, 4H), 3.05 – 2.96 (m, 2H), 2.94 – 2.83 (m, 2H), 1.89 – 1.78 (m, 1H), 1.77 – 1.66 (m, 2H), 1.47 – 1.26 (m, 3H), 1.19 – 1.07 (m, 2H). ¹³C NMR (100 MHz, CD₃OD): δ 174.6, 174.6, 174.5, 172.6, 171.9, 158.6, 158.6, 157.3, 138.7, 131.4, 130.2, 129.5, 128.5, 127.7, 116.4, 58.1, 57.4, 55.7, 55.0, 43.3, 41.8, 41.6, 36.7, 36.4, 29.3, 29.0, 26.2, 26.1.

cyclo(-Arg¹-Arg²-Cha³-Gly⁴-D-Tyr⁵-) × 2 TFA (6). ¹H NMR (400 MHz, CD₃OD): δ 7.03 (d, J = 8.4 Hz, 2H), 6.72 (d, J = 8.4 Hz, 2H), 4.42 – 4.22 (m, 3H), 4.10 (dd, J = 11.2, 3.7 Hz, 1H), 3.86 (dd, J = 32.3, 15.9 Hz, 2H), 3.27 – 3.13 (m, 2H), 3.03 (t, J = 6.7 Hz, 2H), 2.95 – 2.85 (m, 2H), 1.94 – 1.80 (m, 3H), 1.79 – 1.51 (m, 9H), 1.48 – 1.37 (m, 1H), 1.37 – 1.05 (m, 6H), 1.03 – 0.87 (m, 2H). ¹³C NMR (100 MHz, CD₃OD): δ 174.3, 173.1, 173.1, 171.5, 170.6, 157.2, 157.2, 155.9, 130.1, 127.1, 115.0, 56.8, 53.7, 53.6, 52.8, 41.8, 40.4, 40.2, 36.7, 35.3, 34.2, 33.1, 32.4, 27.7, 27.6, 26.1, 25.9, 25.8, 25.0, 24.9.

cyclo(-Arg¹-Arg²-Hph³-Gly⁴-D-Tyr⁵-) × **2 TFA (7).** ¹H NMR (400 MHz, CD₃OD): δ 7.33 – 7.16 (m, 5H), 7.08 (d, J = 8.2 Hz, 2H), 6.74 (d, J = 8.2 Hz, 2H), 4.45-4.30 (m, 2H), 4.19 – 4.02 (m, 3H), 3.73 (d, J = 16.0 Hz, 1H), 3.09 – 2.97 (m, 2H), 2.92 (d, J = 7.9 Hz, 2H), 2.68 (dd, J = 16.1, 8.8 Hz, 2H), 2.29 – 2.08 (m, 2H), 2.09 –1.96 (m, 2H), 1.83 (m, 2H), 1.69 – 1.47 (m, 2H), 1.43 – 1.26 (m, 2H), 1.18 (m, 2H). ¹³C NMR (100 MHz, CD₃OD): δ 175.0, 174.6, 174.5, 172.8, 172.0, 158.6, 157.3, 142.3, 131.5, 129.5, 129.5, 128.6, 127.2, 116.4, 58.2, 55.8, 55.5, 54.6, 46.1, 43.2, 41.9, 41.6, 36.6, 33.3, 32.4, 29.2, 29.0, 26.4, 26.1.

cyclo(-Arg¹-Arg²-Hch³-Gly⁴-D-Tyr⁵-) × 2 TFA (8). ¹H NMR (400 MHz, CD₃OD): δ 7.03 (d, J = 8.5 Hz, 2H), 6.71 (d, J = 8.5 Hz, 2H), 4.38 – 4.28 (m, 2H), 4.13 – 4.05 (m, 2H), 3.91 (d, J = 16.0 Hz, 1H), 3.78 (d, J = 16.0 Hz, 1H), 3.27 – 3.13 (m, 2H), 3.03 (t, J = 6.8 Hz, 2H), 2.93 – 2.86 (m, 2H), 1.91 – 1.75 (m, 4H), 1.74 – 1.50 (m, 8H), 1.28 – 1.08 (m, 9H), 0.95 – 0.80 (m, 2H). ¹³C NMR (100 MHz, CD₃OD): δ 175.6, 174.7, 174.5, 173.0, 172.1, 158.7, 158.7, 157.4, 131.6, 128.7, 116.5, 58.2, 56.9, 55.4, 55.1, 43.4, 41.9, 41.7, 38.8, 36.9, 34.9, 34.6, 34.5, 29.3, 29.1, 28.4, 27.8, 27.5, 26.5, 26.4.

cyclo(-Arg¹-Arg²-Bsa³-Gly⁴-D-Tyr⁵-) × **2 TFA (9).** ¹H **NMR** (400 MHz, CD₃OD): δ 7.36 – 7.24 (m, 4H), 7.22 – 7.17 (m, 1H), 7.04 (d, J = 8.0 Hz, 2H), 6.71 (d, J = 8.0 Hz, 2H), 6.48 (d, J = 15.7 Hz, 1H), 6.24 – 6.13 (m, 1H), 4.38 – 4.24 (m, 3H), 4.09 (dd, J = 11.3, 3.2 Hz, 1H), 4.04 (d, J = 15.9 Hz, 1H), 3.69 (d, J = 15.9 Hz, 1H), 3.10 – 2.97 (m, 4H), 2.91 (d, J = 8.1 Hz, 2H), 2.76 (t, J = 7.2 Hz, 2H), 1.90 – 1.63 (m, 3H), 1.51 (m, 3H), 1.21 – 1.08 (m, 2H). ¹³C **NMR** (100 MHz, CD₃OD): δ 173.2, 173.1, 173.1, 171.3, 170.6, 157.2, 157.1, 155.8, 137.1, 133.0, 130.0, 128.2, 127.2, 127.0, 125.7, 124.9, 115.0, 56.6, 54.5, 54.5, 53.4, 42.0, 40.4, 40.1, 35.3, 35.3, 32.9, 28.0, 27.9, 27.6, 27.5, 24.9, 24.8.

cyclo(-Arg¹-Arg²-1-Nal³-Gly⁴-D-Tyr⁵-) × **2 TFA (10).** ¹**H NMR** (400 MHz, CD₃OD): δ 8.15 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.81 – 7.70 (m, 1H), 7. 52 (dt, J = 14.7 Hz, 2H), 7.41-7.37 (m, 2H), 7.03 (d, J = 8.5 Hz, 2H), 6.71 (d, J = 8.5 Hz, 2H), 4.64 (t, J = 7.5 Hz, 1H), 4.35 (t, J = 8.1 Hz, 1H), 4.14 (t, J = 7.6 Hz, 1H), 4.10 – 3.98 (m, 2H), 3.68 – 3.57 (m, 3H), 3.18 – 3.01 (m, 4H), 2.90 (d, J = 8.7 Hz, 2H), 1.88 – 1.78 (m, 1H), 1.76 – 1.67 (m, 2H), 1.50 – 1.26 (m, 3H), 1.21 – 1.09 (m, 2H). ¹³**C NMR** (100 MHz, CD₃OD): δ 173.2, 173.1, 173.1, 171.3, 170.5, 157.2, 157.1, 155.8, 134.0, 133.2, 131.9, 130.0, 128.5, 127.3, 127.2, 127.2, 125.9, 125.3, 124.9, 123.1, 115.0, 56.5, 55.3, 54.5, 53.5, 42.1, 40.4, 40.1, 35.4, 35.4, 32.2, 27.9, 27.5, 24.8, 24.7.

cyclo(-Arg¹-Arg²-Pph³-Gly⁴-D-Tyr⁵-) × 2 TFA (11). ¹H NMR (400 MHz, CD₃OD): δ 7.55 (m, 4H), 7.40 (t, J = 7.6 Hz, 2H), 7.31 (d, J = 7.7 Hz, 3H), 7.03 (d, J = 8.4 Hz, 2H), 6.71 (d, J = 8.4 Hz, 2H), 4.50 (t, J = 7.7 Hz, 1H), 4.34 (m, 1H), 4.24 (m, 1H), 4.10 – 3.98 (m, 2H), 3.71 (d, J = 15.7 Hz, 1H), 3.27 – 3.07 (m, 4H), 3.02 (t, J = 6.5 Hz, 2H), 2.97 – 2.83 (m, 2H), 1.92 – 1.70 (m, 3H), 1.50 – 1.35 (m, 3H), 1.19 – 1.06 (m, 2H). ¹³C NMR (100 MHz, CD₃OD): δ 173.2, 173.2, 173.1, 171.4, 170.5, 157.2, 157.1, 155.9, 140.5, 139.5, 136.5, 130.0, 129.4, 128.5, 127.1, 126.9, 126.6, 126.4, 115.0, 56.7, 56.1, 54.2, 53.6, 42.0, 40.4, 40.2, 35.4, 34.7, 28.0, 27.6, 24.9, 24.8.

cyclo(-Arg¹-Arg²-Bph³-Gly⁴-D-Tyr⁵-) × **2 TFA (12).** ¹**H NMR** (400 MHz, CD₃OD): δ 7.77 – 7.66 (m, 4H), 7.62 (m, 1H), 7.51 (t, J = 4.0, 8.0 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 7.00 (d, J = 8.0 Hz, 2H), 6.70 (d, J = 8.0 Hz, 2H), 4.53 (t, J = 7.8 Hz, 1H), 4.31 (dd, J = 9.6, 6.7 Hz, 1H), 4.19 (t, J = 7.5 Hz, 1H), 4.11 – 4.00 (m, 2H), 3.65 (d, J = 15.7 Hz, 1H), 3.17 – 3.03 (m, 3H), 3.05 – 2.95 (m, 3H), 2.92 – 2.81 (m, 2H), 1.88 – 1.77 (m, 1H), 1.78 – 1.63 (m, 2H), 1.46 – 1.26 (m, 3H), 1.18 – 1.05 (m, 2H). ¹³**C NMR** (100 MHz, CD₃OD): δ 198.7, 174.9, 174.7, 174.5, 172.9, 172.2, 158.8, 157.5, 144.7, 139.0, 137.5, 134.1, 131.7, 131.5, 131.2, 130.7, 129.7, 128.7, 116.6, 58.4, 57.1, 56.0, 55.1, 43.5, 42.0, 41.8, 36.9, 36.8, 36.5, 29.6, 29.2, 26.4, 26.4.

cyclo(-Arg¹-Arg²-Ala³-Gly⁴-D-Tyr⁵-)× **2 TFA (13).** ¹**H NMR** (400 MHz, CD₃OD): δ ¹H NMR (400 MHz, CD₃OD) δ 7.06 (d, J = 8.4 Hz, 2H), 6.73 (d, J = 8.4 Hz, 2H), 4.42 – 4.15 (m, 3H), 4.13 (dd, J = 11.4, 3.8 Hz, 1H), 4.03 (d, J = 15.8 Hz, 1H), 3.73 (d, J = 15.8 Hz, 1H), 3.28 – 3.17 (m, 2H), 3.08 – 2.99 (m, 2H), 2.96 – 2.88 (m, 2H), 1.99 – 1.74 (m, 3H), 1.69 – 1.44 (m, 3H), 1.41 (d, J = 7.1 Hz, 3H), 1.33 – 0.94 (m, 2H). ¹³C NMR (100 MHz, CD₃OD): δ 175.9, 174.7, 174.6, 172.7, 172.2, 158.7, 157.4, 131.6, 128.5, 116.5, 58.3, 55.4, 54.9, 51.7, 43.3, 41.9, 41.7, 36.8, 29.3, 29.1, 26.4, 26.3, 15.8.

cyclo(-Arg¹-Arg²-2-Nal³-Gly⁴-D-Phe⁵-) × **2 TFA (14).** ¹H NMR (400 MHz, CD₃OD): δ 7.83 – 7.74 (m, 3H), 7.70 (s, 1H), 7.49 – 7.36 (m, 3H), 7.30 – 7.16 (m, 5H), 4.60 (dd, J = 9.0,6.7 Hz, 1H), 4.43 (t, J = 8.05 Hz, 1H), 4.16 (t, J = 7.62 Hz, 1H), 4.09-4.00 (m, 2H), 3.70 (d, J = 15.71 Hz, 1H), 3.37 – 3.33 (m, 2H), 3.04 – 2.93 (m, 6H), 1.86 – 1.74 (m, 1H), 1.75 – 1.64 (m, 2H), 1.49 – 1.38 (m, 1H), 1.37 – 1.17 (m, 2H), 1.16 – 1.04 (m, 2H). ¹³C NMR (100 MHz, CD₃OD): δ 174.6, 174.5, 174.3, 172.7, 171.9, 158.5, 158.5, 137.8, 136.2, 134.9, 133.8, 130.4, 129.6, 129.1, 128.9, 128.9, 128.6, 128.6, 128.5, 128.4, 127.9, 127.2, 126.7, 57.7, 57.2, 55.8, 55.1, 43.5, 41.7, 41.5, 37.6, 36.7, 29.3, 28.9, 26.2, 26.0.

cyclo(-Arg¹-Arg²-2-Nal³-Gly⁴-Aic⁵-) × **2 TFA (15).** ¹**H NMR** (400 MHz, CD₃OD): δ 7.85 – 7.75 (m, 3H), 7.72 (s, 1H), 7.49 – 7.38 (m, 3H), 7.27 – 7.15 (m, 4H), 4.71 (m, 1H), 4.49 – 4.37 (m, 1H), 3.96-3.88 (m, 1H), 3.86 – 3.75 (m, 2H), 3.57 (d, *J* = 14.0 Hz, 1H), 3.46 – 3.32 (m, 3H), 3.28 – 3.07 (m, 4H), 3.00 – 2.88 (m, 2H), 1.93 – 1.72 (m, 4H), 1.67 – 1.46 (m, 2H), 1.36 – 1.24 (m, 1H), 1.24 – 1.10 (m, 1H). ¹³**C NMR** (100 MHz, CD₃OD): δ 174.5, 172.9, 172.6, 172.1, 170.1, 157.1, 157.0, 140.6, 138.7, 134.9, 133.5, 132.4, 127.7, 127.5, 127.2, 127.1, 127.0, 126.8, 126.5, 125.8, 125.3, 124.2, 124.1, 67.3, 56.5, 55.0, 53.0, 43.4, 42.4, 41.4, 40.3, 40.3, 36.3, 28.5, 26.9, 24.9, 24.8.

cyclo(-Arg¹-Arg²-2-Nal³-Gly⁴-D-Tic⁵-) × **2 TFA (16).** ¹**H NMR** (400 MHz, CD₃OD): δ 7.82 – 7.72 (m, 3H), 7.73 (s, 1H), 7.47 – 7.31 (m, 3H), 7.27 – 7.17 (m, 4H), 4.72 (t, J = 8.00 Hz, 1H), 4.65 (d, J = 14.5 Hz, 1H), 4.52 (d, J = 14.5 Hz, 1H), 4.39 – 4.25 (m, 3H), 4.21 – 4.11 (m, 2H), 3.33 (d, J = 8.02 Hz, 2H), 3.19 (t, J = 6.43 Hz, 2H), 3.07 – 3.02 (m, 2H), 2.91 – 2.83 (m, 2H), 2.08 – 1.96 (m, 1H), 1.77 – 1.61 (m, 5H), 1.31 – 1.16 (m, 1H), 1.15 – 1.06 (m, 1H). ¹³C **NMR** (100 MHz, CD₃OD) δ 175.4, 175.3, 174.2, 172.5, 170.4, 158.7, 158.4, 136.4, 135.4, 134.9, 134.9, 133.8, 129.2, 128.9, 128.6, 128.5, 128.3, 128.3, 128.2, 127.2, 127.0, 126.7, 58.8, 57.1, 56.2, 54.8, 46.4, 42.7, 41.8, 41.7, 36.1, 31.8, 29.5, 29.4, 26.6, 25.9.

 $cyclo(-Arg^1-Arg^2-2-Nal^3-Gly^4-trans-Ppr^5-) \times 2$ TFA (17). Obtained as a mixture of the two diastereomers in a ratio of 47:53 (as determined by analytical HPLC) after purification, and not characterized by NMR.

 $cyclo(-Arg^1-Arg^2-2-Nal^3-Gly^4-cis-Ppr^5-) \times 2$ TFA (18). Obtained as a mixture of the two diastereomers in a ratio of 68:32 (as determined by analytical HPLC) after purification, and not characterized by NMR.

cyclo(-Arg¹-Arg²-2-Nal³-Gly⁴-D-Pic⁵-) × 2 TFA (19). ¹H NMR (400 MHz, CD₃OD): δ 7.87 – 7.77 (m, 3H), 7.75 (s, 1H), 7.52 – 7.37 (m, 3H), 4.73 (t, *J* = 7.96 Hz, 1H), 4.38 – 4.26 (m, 2H), 4.27 – 4.17 (m, 2H), 3.93 (d, *J* = 16,4 Hz, 1H), 3.65 – 3.56 (m, 2H), 3.38 (d, *J* = 8.10 Hz, 2H), 3.21 (t, *J* = 6.44 Hz, 2H), 2.95 (m, 2H), 2.24 – 2.14 (m, 2H), 2.11 – 1.94 (m, 4H), 1.82 – 1.58 (m, 6H), 1.34 – 1.11 (m, 2H). ¹³C NMR (100 MHz, CD₃OD): δ 175.6, 175.2, 174.6, 173.6, 172.1, 157.9, 157.2, 135.5, 134.3, 133.3, 129.4, 129.0, 128.7, 128.5, 128.3, 127.7, 127.2, 58.6, 57.1, 56.1, 55.1, 54.4, 44.6, 44.0, 41.5, 41.3, 37.0, 28.3, 28.3, 26.2, 25.7, 24.9, 20.4.

cyclo(-Arg¹-Arg²-2-Nal³-Gly⁴-D-Pro⁵-) × 2 TFA (20). ¹H NMR (400 MHz, CD₃OD): δ 7.88 – 7.80 (m, 3H), 7.77 (s, 1H), 7.53-7.43 (m, 3H), 4.75 (t, *J* = 8.0 Hz, 1H), 4.41 – 4.28 (m, 2H), 4.28 – 4.17 (m, 2H), 3.90 (d, *J* = 16.4 Hz, 1H), 3.66 – 3.56 (m, 2H), 3.39 (d, *J* = 12.4 Hz, 2H), 3.22 (t, *J* = 6.4 Hz, 2H), 2.99 – 2.92 (m, 2H), 2.28 – 2.11 (m, 2H), 2.15 – 1.92 (m, 3H), 1.83 – 1.63 (m, 5H), 1.33 – 1.08 (m, 2H). ¹³C NMR (100 MHz, CD₃OD): δ 174.3, 174.0, 172.9, 172.8, 171.1, 168.1, 157.2, 157.0, 135.0, 133.5, 132.4, 127.7, 127.4, 127.2, 127.1, 126.9, 125.8, 125.3, 61.1, 55.9, 54.6, 54.5, 53.5, 46.0, 41.2, 40.4, 34.5, 28.1, 27.9, 25.2, 25.2, 24.5.

cyclo(-Arg¹-Arg²-2-Nal³-Gly⁴-D-Ala⁵-) × 2 TFA (21). ¹H NMR (400 MHz, CD₃OD): δ 7.80 – 7.73 (m, 3H), 7.66 (s, 1H), 7.46 – 7.33 (m, 3H), 4.61 (dd, J = 9.1, 6.3 Hz, 1H), 4.38 – 4.30 (m, 1H), 4.30 – 4.22 (m, 1H), 4.05 (t, J = 7.7 Hz, 1H), 3.94 (d, J = 15.7 Hz, 1H), 3.67 (d, J = 15.8 Hz, 1H), 3.35 – 3.14 (m, 4H), 2.98 – 2.88 (m, 2H), 1.96 – 1.85 (m, 1H), 1.76 – 1.54 (m, 5H), 1.35 – 1.31 (m, 1H), 1.27 (d, J = 6.9 Hz, 3H), 1.24 – 1.13 (m, 1H). ¹³C NMR (100 MHz, CD₃OD): δ 175.7, 174.9, 174.8, 173.3, 172.0, 158.8, 158.7, 136.3, 135.1, 134.1, 129.3, 129.2, 128.9, 128.7, 127.4, 126.9, 56.9, 56.8, 55.3, 50.9, 44.3, 41.0, 41.9, 37.8, 29.3, 29.2, 26.7, 26.3, 16.7.

cyclo(-Arg¹-Arg²-2-Nal³-Gly⁴-Gly⁵-) × **2 TFA (22).** ¹**H NMR** (400 MHz, CD₃OD): δ 7.82 – 7.72 (m, 3H), 7.61 (s, 1H), 7.46 – 7.33 (m, 3H), 4.47 (dd, J = 10.3, 4.8 Hz, 1H), 4.22 – 4.13 (m, 2H), 4.09 – 3.98 (m, 2H), 3.77 (d, J = 15.1 Hz, 1H), 3.58 (d, J = 16.4 Hz, 1H), 3.38 (dd, J = 13.7, 4.9 Hz, 1H), 3.24 – 3.15 (m, 3H), 2.89 – 2.80 (m, 2H), 1.93 – 1.76 (m, 2H), 1.73 – 1.50 (m, 3H), 1.49 – 1.37 (m, 1H), 1.37 – 1.19 (m, 2H). ¹³**C NMR** (100 MHz, CD₃OD): δ 175.1, 174.4, 174.2, 173.0, 172.7, 158.8, 158.6, 136.6, 135.1, 134.1, 129.5, 129.4, 128.9, 128.6, 128.6, 127.5, 126.9, 56.7, 56.5, 55.7, 55.7, 44.7, 43.6, 41.9, 41.8, 37.7, 31.0, 28.7, 26.8, 26.3.

¹H and ¹³C NMR spectra



































































HPLC chromatograms





